Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings, Inc. engages in the development of novel therapies for cancer. The company is headquartered in Rockville, MD.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. It also offers cancer treatments with surgery, radiation therapy, chemotherapy, and immunotherapy. The company was founded by Anatoly Dritschilo, Mira Jung, and Milton Brown on December 18, 2012 and is headquartered in Gaithersburg, MD.

ROCKVILLE, Md. , Sept. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled "Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof.

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

ROCKVILLE, Md. , Aug. 29, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of Shuttle's lead Histone deacetylase 6 (HDAC6) inhibitor drug candidate (SP-2-225) to stimulate the innate immune system following radiation therapy.

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

ROCKVILLE, Md. , Aug. 3, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that TCG GreenChem has successfully completed the initial manufacturing campaign for the active pharmaceutical ingredient (API) of Ropidoxuridine for use in the Company's upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy.

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

ROCKVILLE, Md. , May 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

Faraday Future Intelligent Electric

Heartcore Enterprises

Penny stocks present an intriguing opportunity for individuals seeking to grow wealth on a budget. This realm of the financial market is celebrated for its high-yield potential, making it a lucrative proposition for those with modest portfolios.

Trading Penny Stocks on a Budget, Maximizing Returns

ROCKVILLE, Md. , May 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) (the "Company," or "Shuttle Pharmaceuticals"), announced today that its Chief Executive Officer, Anatoly Dritschilo, M.D.

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

ROCKVILLE, Md. , March 22, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered a research agreement with Georgetown University focused on the evaluation of the Company's lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model.

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

ROCKVILLE, Md. , March 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2022.

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

ROCKVILLE, Md. , March 9, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has signed an agreement with the University of Iowa (UI) Pharmaceuticals for formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine.

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

ROCKVILLE, Md. , Feb. 23, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered an agreement to lease new laboratory and office space, commencing in June 2023, to complement the development of the Company's lead drug candidates and accelerate broader diagnostic capabilities on predictive biomarkers.

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

ROCKVILLE, Md. , Jan. 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced Anatoly Dritschilo, M.D.

Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31

ROCKVILLE, Md. , Jan. 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Chairman and Chief Executive Officer, Anatoly Dritschilo, M.D.

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023

Bitfarms Ltd

Jasper Therapeutics

Solid Power

Penny stocks to watch before next week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 4 Hot Stocks With Big News This Week

ROCKVILLE, Md. , Jan. 12, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, announced the issuance of a $4.3 million senior secured convertible note and warrant to an institutional investor.

Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants

ROCKVILLE, Md. , Jan. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript discussing immune responses taking place in patients after radiation therapy for cancer.

Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

ComSovereign Holding

Digital Brands Group Inc

Can these tips for trading penny stocks help you to profit? The post Tips for Buying Penny Stocks Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Tips for Buying Penny Stocks Under $3 Right Now

ROCKVILLE, Md. , Nov. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update

ROCKVILLE, Md. , Nov. 3, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side effects, today announced it has engaged Theradex Oncology, a leading clinical research organization ("CRO"), to help prepare for its upcoming clinical study of Ropidoxuridine.

Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study

ROCKVILLE, Md. , Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director.

Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors

Akero Therapeutics Inc

Applied DNA Sciences

Avenue Therapeutics

HeartBeam

Immuneering Corp

Mind Medicine MindMed

PhaseBio Pharmaceuticals Inc

Spero Therapeutics

Virios Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md. , Sept. 20, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side effects, entered into an agreement with TCG GreenChem, Inc. to manufacture Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, for use in formulating the drug product for testing in clinical trials of Ropidoxuridine and RT of cancers.

Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine

Company awarded patents in the U.S. and Hong Kong ROCKVILLE, Md. , Sept. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company, announced today that it has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing side effects and improving outcomes for cancer patients treated with radiation therapy (RT).

Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment

The stock, after dropping big-time following its IPO last week, had a successful run-up this week.

Why Shares of Shuttle Pharmaceuticals Jumped 160.4% This Week

There have been plenty of intriguing initial public offerings (IPOs) for investors to follow this year. However, among the most bizarre IPOs of late has been that of Shuttle Pharmaceuticals (NASDAQ: SHPH ).

News for Shuttle Pharmaceuticals Holdings Inc Stock (SHPH)